8-K: Evolus Announces CFO Sandra Beaver's Voluntary Resignation Amidst Strong Company Momentum

Evolus, Inc. announced that Chief Financial Officer Sandra Beaver will voluntarily resign effective June 13, 2025, to pursue another opportunity, with the company emphasizing her departure is not due to disagreements and highlighting recent record revenues and strategic positioning for profitability.

Summary

• Evolus, Inc. announced the voluntary resignation of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025.
• Mrs. Beaver is departing to accept the same position at a private mental health and wellness technology company.
• Her resignation was not due to any disagreement with the company's operations, policies, practices, accounting principles, financial statements, or disclosures.
• The company has initiated a search for her successor, with the experienced Finance team managing the transition in the interim.
• Evolus highlighted strong momentum, including the recent launch of a second product line, achievement of record revenues, a solidified balance sheet, and positioning for profitability.

Sentiment

Score: 7

Explanation: The sentiment is generally positive despite the CFO's departure, as the company explicitly states the resignation was voluntary and not due to disagreements. Management highlights strong recent performance (record revenues, solidified balance sheet) and a positive future outlook (positioned for profitability, new product launch), framing the transition as a continuation of success.

Positives

• Sandra Beaver's resignation is voluntary and not due to any disagreements with the company's operations, policies, or financial practices.
• Evolus has recently launched its second product line, indicating business expansion.
• The company has achieved record revenues, demonstrating strong financial performance.
• Evolus has solidified its balance sheet, suggesting financial stability.
• The company is positioned for profitability, indicating a positive future financial outlook.

Risks

• Uncertainties associated with the ability to comply with the terms and conditions in the Medytox Settlement Agreements.
• Ability to fund future operations or obtain financing.
• Unfavorable global economic conditions, including trade disputes and tariffs, and their impact on consumer discretionary spending.
• Uncertainties related to customer and consumer adoption of Jeuveau and Evolysse products.
• Efficiency and operability of the company's digital platform.
• Competition and market dynamics in the aesthetic injectable market.
• Ability to successfully launch and commercialize products in new markets, including Evolysse HA gels in the U.S. and Estyme HA gels in Europe.
• Ability to maintain regulatory approvals for Jeuveau and Evolysse or obtain approvals for new product candidates or indications.
• Reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse HA gel products in the U.S.

Future Outlook

Evolus expects to continue its strong momentum, having recently launched a second product line, achieved record revenues, solidified its balance sheet, and positioned itself for profitability. The company is actively searching for a successor to the CFO role and anticipates a smooth transition with the existing finance team.

Management Comments

• David Moatazedi, President and CEO of Evolus, stated: "On behalf of our employees, our leadership team, and our Board of Directors, I want to thank Sandra for her contributions to Evolus. Her stewardship across several important functions has helped drive our consistent growth and positioned the company for continued success. We enter this next chapter with strong momentum, having recently launched our second product line, achieved record revenues, solidified the balance sheet, and positioned the company for profitability. We wish Sandra continued success as she takes on this new opportunity."
• Sandra Beaver, Chief Financial Officer, commented: "It has been an honor to serve as CFO of Evolus and to lead such a talented Finance organization. I'm incredibly proud of what we've accomplished together. The Finance team at Evolus is exceptional, and I am confident they will continue to support the company's strategic and financial objectives moving forward. I leave the company knowing that it is well positioned for continued success and I am excited for its future."

Industry Context

Evolus operates as a global performance beauty company focused on redefining the aesthetic injectable market. Its core products, Jeuveau (a neurotoxin) and Evolysse (hyaluronic acid gels), target the next generation of beauty consumers through a customer-centric business model and digital platform. The company's strategic moves, such as launching new product lines and aiming for profitability, reflect its ambition to become a leader in the competitive aesthetics industry.

Management Changes

Legal Proceedings

• The company's forward-looking statements are subject to risks and uncertainties, including those associated with its ability to comply with the terms and conditions in the Medytox Settlement Agreements.

Stakeholder Impact

• Shareholders: Potential impact due to the departure of a key executive, though mitigated by the company's positive framing and emphasis on continued strong performance.
• Employees: The finance team will manage the transition, ensuring continuity, but a leadership change can affect morale and team dynamics.
• Customers/Consumers: No direct immediate impact on product availability or service is indicated.
• Creditors: The company's solidified balance sheet and positioning for profitability suggest continued financial health, which is positive for creditors.

Next Steps

• Initiate a search to identify a successor for the Chief Financial Officer position.
• Provide updates on the CFO search as appropriate.
• The experienced Finance team will continue leading accounting, finance, and investor relations functions to ensure a smooth transition.

Key Dates

Keywords

Evolus, EOLS, CFO resignation, Chief Financial Officer, management change, aesthetic beauty, neurotoxin, Jeuveau, Evolysse, performance beauty, SEC filing, 8-K